Back to Home

Valion Bio

NASDAQ: VBIO $0.30 USD~$50M MCAP

Valion Bio is a clinical-stage biodefense and infectious disease company. Recently announced that Ukraine's Ministry of Health accepted the Company's regulatory dossier for Entolimod under a regulatory equivalence pathway.

Company Info

Sector:Biodefense
Headquarters:USA
Founded:2019

Upcoming Milestones & Key Dates

Q3 2026
Regulatory

Ukraine MoH review completion

Clinical Development Pipeline

Entolimod

Target: TLR5 agonist
Radiation countermeasure
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Entolimod

Target: TLR5 agonist
Cancer immunotherapy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Undisclosed

Target: TBD
Infectious disease
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

To be confirmed

Chief Executive Officer

To be confirmed

Chief Medical Officer

To be confirmed

Chief Scientific Officer

Careers & Job Openings

See all open roles

Various
USA
Apply Now